Celldex Therapeutics (CLDX) Interest Coverage Ratio (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Interest Coverage Ratio of 231.96 for Q1 2026, up 38.99% year-over-year from 166.89 in Q1 2025, and up 98.94% quarter-over-quarter from 21788.25 in Q4 2025.
Celldex Therapeutics (CLDX) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Interest Coverage Ratio history runs 16 years deep, the most recent figure standing at 231.96 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 38.99% year-over-year to 231.96; the TTM figure through Mar 2026 stood at 849.07 (up 35.5% YoY), while the FY2025 annual figure was 0.77, down 25.77% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 231.96, up from 21788.25 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 0.09 in Q4 2022, with the low at 24539.0 in Q3 2025.
- The 5-year median for Interest Coverage Ratio is 63.01 (2023), against an average of 3121.05.
- The sharpest annual moves came in 2022 and 2025: Interest Coverage Ratio jumped 96.91% in 2022, then slumped 12434839.7% in 2025.
- Celldex Therapeutics' Interest Coverage Ratio stood at 0.09 in 2022, then plunged by 53.78% to 0.14 in 2023, then decreased by 27.8% to 0.18 in 2024, then plunged by 12434839.7% to 21788.25 in 2025, then surged by 98.94% to 231.96 in 2026.
- Business Quant data shows CLDX's Interest Coverage Ratio at 231.96 in Q1 2026, 21788.25 in Q4 2025, and 24539.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -58.30 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.30 |
| Mar 31, 2026 | -231.96 |
| Dec 31, 2025 | -21,788.25 |
| Sep 30, 2025 | -24,539.00 |
| Jun 30, 2025 | -541.16 |
| Mar 31, 2025 | -380.24 |
| Dec 31, 2024 | -0.18 |
| Sep 30, 2024 | -5,212.60 |
| Jun 30, 2024 | -48.60 |
| Mar 31, 2024 | -70.99 |
| Dec 31, 2023 | -0.14 |
| Sep 30, 2023 | -88.88 |
| Jun 30, 2023 | -63.01 |
| Mar 31, 2023 | -61.04 |
| Dec 31, 2022 | -0.09 |
| Sep 30, 2022 | -10.23 |
| Jun 30, 2022 | -12.08 |
| Mar 31, 2022 | -9.35 |
| Dec 31, 2021 | -0.07 |
| Sep 30, 2021 | -330.54 |